Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582400 · ClinicalTrials.gov registry record · Phase 2
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00582400 is a Phase 2 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 9 participants.
The verdict
NCT00582400, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the patterns of failure and survival. The primary response measurements will be the achievement of an objective tumor response, response duration and progression-free survival
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582400
The ClinicalTrials.gov registry entry for NCT00582400 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00582400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582400 about?
NCT00582400 is a clinical study titled "A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver". The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the...
What is the current status of trial NCT00582400?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00582400?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00582400?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.